Pedro Barata, MD
Hematology & Oncology · New Orleans, LANPI 1841746542
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Pfizer at 40.8% of the total. 2025 is the largest year on record at $331,931, 8.6 times the $38,768 reported in 2019. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 723 payments — averaging $1283.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$378K
- Astellas Pharma US Inc$115K
- Bayer$98K
- Merck$69K
- AstraZeneca$51K
- Exelixis Inc.$43K
- plus $174K from 30 others
Across 437 payments — averaging $7646.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$1.2M
- Janssen Research & Development, LLC$918K
- Merck$489K
- AVEO Pharmaceuticals, Inc.$283K
- Seagen Inc.$122K
- Sumitomo Pharma America, Inc.$103K
- plus $220K from 5 others
What the payments were for
- Consulting fees$408,13844%
- Speaking & faculty fees$336,06736%
- Travel & lodging$159,97217%
- Food & beverage$22,9122%
- Education$5840%
- Entertainment$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 134 | $378,424 |
| Astellas Pharma US Inc | 104 | $114,730 |
| Bayer | 80 | $98,142 |
| Merck | 50 | $68,926 |
| AstraZeneca | 49 | $50,971 |
| Exelixis Inc. | 53 | $42,687 |
| Sanofi | 23 | $40,718 |
| EMD Serono, Inc. | 26 | $29,550 |
| Ipsen Innovation | 4 | $18,202 |
| Telix Pharmaceuticals | 38 | $17,885 |
| E.r. Squibb & Sons, L.L.C. | 22 | $13,404 |
| Eisai Inc. | 24 | $11,868 |
| AVEO Pharmaceuticals, Inc. | 13 | $7,980 |
| Johnson & Johnson | 8 | $7,178 |
| Seagen Inc. | 10 | $4,836 |
| Janssen Scientific Affairs, LLC | 7 | $4,388 |
| Astellas Pharma Europe Ltd | 2 | $3,570 |
| Dendreon Pharmaceuticals LLC | 16 | $3,057 |
| Janssen Research & Development, LLC | 2 | $2,800 |
| Myovant Sciences Inc. | 8 | $2,788 |
| Ipsen Pharma SAS | 1 | $1,740 |
| Astrazeneca UK Limited | 12 | $1,439 |
| Sanofi-aventis U.S. LLC | 5 | $435 |
| Caris MPI, Inc. | 8 | $379 |
| Novartis | 5 | $361 |
| Clovis Oncology, Inc. | 3 | $279 |
| Sumitomo Pharma America, Inc. | 3 | $242 |
| Gilead | 3 | $155 |
| Roche Diagnostics Corporation | 1 | $113 |
| Lilly USA, LLC | 2 | $108 |
| Regeneron Healthcare Solutions, Inc. | 1 | $100 |
| Boston Scientific | 2 | $97 |
| Coherus Oncology, Inc. | 1 | $94 |
| Genentech, Inc. | 1 | $43 |
| Astellas Pharma Global Development | 1 | $33 |
| Amgen | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$927,746 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 78 | $1,098,158 |
| CabometyxCabozantinib S-Malate | 41 | $1,086,296 |
| NubeqaDarolutamide | 19 | $259,824 |
| Abiraterone Acetate | 145 | $224,517 |
| OrgovyxRelugolix | 34 | $99,561 |
| Ondansetron Hcl | 37 | $588 |
| Prednisone | 176 | $474 |
| Bicalutamide | 16 | $384 |
| Dexamethasone | 26 | $378 |
| Prochlorperazine Maleate | 13 | $138 |
| Levothyroxine Sodium | 23 | $136 |
| Tamsulosin Hcl | 13 | $119 |
| Olanzapine | 17 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $114,730 | $1,098,15878 claims |
| Exelixis Inc.Cabometyx | $42,687 | $1,086,29641 claims |
| BayerNubeqa | $98,142 | $259,82419 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $4,388 | $224,517145 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $242 | $99,56134 claims |
| Lilly USA, LLCOlanzapine | $108 | $9617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in New Orleans
- Maissaa JanbainNew Orleans$862K
- Marc MatranaNew Orleans$757K
- Lingling duNew Orleans$173K
- Cindy LeissingerNew Orleans$135K
- Carter DavisNew Orleans$61K
- Furhan YunusNew Orleans$55K
- Michelle LochNew Orleans$50K
- David MorrisonNew Orleans$23K
- Scott SonnierNew Orleans$20K
- Ralph MillettNew Orleans$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.